Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

Angiotensin Receptor 1 Antibodies

Close filters
No results were found for the filter!
NEW
pS326/pS328-AT1 (phospho-Angiotensin Receptor 1 Antibody)
pS326/pS328-AT1 (phospho-Angiotensin Receptor 1...
Serine326/Serine328 (S326/S328) is major phosphorylation site of the Angiotensin Receptor 1 (AT1). The pS326/pS328-AT1 antibody detects phosphorylation in response to agonists. S326/S328 phosphorylation is likely to be involved in...
$ 375.00 *
NEW
Agonist-induced Serine348/Threonine349 phosphorylation of the Angiotensin Receptor 1
pS348/pT349-AT1 (phospho-Angiotensin Receptor 1...
Serine348/Threonine349 (S348/T349) is major phosphorylation site of the Angiotensin Receptor 1 (AT1). The pS348/pT349-AT1 antibody detects phosphorylation in response to agonists. S348/T349 phosphorylation is likely to be involved in...
$ 375.00 *
NEW
Agonist-induced Serine338/Serine342 phosphorylation of the Angiotensin Receptor 1
pS338/pS342-AT1 (phospho-Angiotensin Receptor 1...
Serine338/Serine342 (S338/S342) is major phosphorylation site of the Angiotensin Receptor 1 (AT1). The pS338/pS342-AT1 antibody detects phosphorylation in response to agonists. S338/S342 phosphorylation is likely to be involved in...
$ 375.00 *
NEW
Agonist-induced Serine331/Threonine332 phosphorylation of the Angiotensin Receptor 1
pS331/pT332-AT1 (phospho-Angiotensin Receptor 1...
Serine331/Threonine332 (S331/T332) is major phosphorylation site of the Angiotensin Receptor 1 (AT1). The pS331/pT332-AT1 antibody detects phosphorylation in response to agonists. S331/T332 phosphorylation is likely to be involved in...
$ 375.00 *
SAMPLE PACK
Agonist-induced Serine331/Threonine332 phosphorylation of the Angiotensin Receptor 1
AT1 Sample Pack (phospho- and...
AT1 Sample Pack consisting of all four available phospho- and non-phospho-AT1 Antibodies 7 x 20 µL trial size each.
$ 300.00 *
NEW
Agonist-induced Serine346/Serine347 phosphorylation of the Angiotensin Receptor 1
pS346/pS347-AT1 (phospho-Angiotensin Receptor 1...
Serine346/Serine347 (S346/S347) is major phosphorylation site of the Angiotensin Receptor 1 (AT1). The pS346/pS347-AT1 antibody detects phosphorylation in response to agonists. S346/S347 phosphorylation is likely to be involved in...
$ 375.00 *
NEW
Agonist-induced Serine335/Threonine336 phosphorylation of the Angiotensin Receptor 1
pS335/pT336-AT1 (phospho-Angiotensin Receptor 1...
Serine335/Threonine336 (S335/T336) is major phosphorylation site of the Angiotensin Receptor 1 (AT1). The pS335/pT336-AT1 antibody detects phosphorylation in response to agonists. S335/T336 phosphorylation is likely to be involved in...
$ 375.00 *
NEW
Validation of the Angiotensin Receptor 1 in transfected HEK293 cells
AT1 (GP-non-phospho) Angiotensin Receptor 1...
The non-phospho-AT1 receptor antibody is directed against the distal part of the carboxyl-terminal tail of human Angiotensin Receptor 1 (AT1). It can be used to detect total AT1 receptors in Western blots independent of phosphorylation....
$ 375.00 *
NEW
Validation of the Angiotensin Receptor 1 in transfected HEK293 cells
AT1 (non-phospho-Angiotensin Receptor 1 Antibody)
The non-phospho-AT1 receptor antibody is directed against the distal part of the carboxyl-terminal tail of human Angiotensin Receptor 1 (AT1). It can be used to detect total AT1 receptors in Western blots independent of phosphorylation....
$ 375.00 *

The angiotensin II type 1 receptor (AT₁R), encoded by AGTR1, is a class A G protein-coupled receptor activated by the endogenous peptide angiotensin II. It is expressed in vascular smooth muscle, the kidneys, the adrenal cortex, and the heart. AT₁R signals predominantly through Gq/11, activating phospholipase C and increasing intracellular calcium. This pathway contributes to vasoconstriction and aldosterone secretion, while renal AT₁R signaling promotes sodium retention. Sustained AT₁R activation can promote inflammation, fibrosis, and cardiovascular remodeling. Agonist-induced phosphorylation by GRK2/3 and GRK5/6 promotes β-arrestin recruitment, which contributes to receptor desensitization and internalization. The synthetic peptide TRV027 preferentially recruits β-arrestin over activating G proteins and has been evaluated in clinical trials, including in acute heart failure. Selective AT₁R antagonists such as losartan, valsartan, and candesartan are used clinically to treat hypertension and, depending on the drug, heart failure or diabetic kidney disease. Intravenous angiotensin II is approved as a vasopressor for adults with septic or other distributive shock. AT1 receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine326/serine328 (pS326/pS328-AT1), serine331/threonine332 (pS331/pT332-AT1), serine335/threonine336 (pS335/pT336-AT1), serine338/serine342 (pS338/pS342-AT1), serine346/serine347 (pS346/pS347-AT1), and serine348/serine349 (pS348/pS349-AT1. This nomenclature refers to the human AT1 receptor. For more information on AT1 pharmacology please refer to the IUPHAR database. For further reading refer to:

de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000 Sep;52(3):415-72. PMID: 10977869.

Alexander W, Bernstein KE, Catt KJ, de Gasparo M, Dhanachandra Singh K, Eguchi S, Escher E, Goodfriend TL, Horiuchi M, Hunyady L, Husain A, Inagami T, Karnik S, Kemp J, Thomas WG, Timmermans PBMWM, Tirupula K, Unal H, Unger T, Vanderheyden P. Angiotensin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4).

The angiotensin II type 1 receptor (AT₁R), encoded by AGTR1 , is a class A G protein-coupled receptor activated by the endogenous peptide angiotensin II. It is expressed in vascular smooth... read more »
Close window
Angiotensin Receptor 1 Antibodies

The angiotensin II type 1 receptor (AT₁R), encoded by AGTR1, is a class A G protein-coupled receptor activated by the endogenous peptide angiotensin II. It is expressed in vascular smooth muscle, the kidneys, the adrenal cortex, and the heart. AT₁R signals predominantly through Gq/11, activating phospholipase C and increasing intracellular calcium. This pathway contributes to vasoconstriction and aldosterone secretion, while renal AT₁R signaling promotes sodium retention. Sustained AT₁R activation can promote inflammation, fibrosis, and cardiovascular remodeling. Agonist-induced phosphorylation by GRK2/3 and GRK5/6 promotes β-arrestin recruitment, which contributes to receptor desensitization and internalization. The synthetic peptide TRV027 preferentially recruits β-arrestin over activating G proteins and has been evaluated in clinical trials, including in acute heart failure. Selective AT₁R antagonists such as losartan, valsartan, and candesartan are used clinically to treat hypertension and, depending on the drug, heart failure or diabetic kidney disease. Intravenous angiotensin II is approved as a vasopressor for adults with septic or other distributive shock. AT1 receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine326/serine328 (pS326/pS328-AT1), serine331/threonine332 (pS331/pT332-AT1), serine335/threonine336 (pS335/pT336-AT1), serine338/serine342 (pS338/pS342-AT1), serine346/serine347 (pS346/pS347-AT1), and serine348/serine349 (pS348/pS349-AT1. This nomenclature refers to the human AT1 receptor. For more information on AT1 pharmacology please refer to the IUPHAR database. For further reading refer to:

de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000 Sep;52(3):415-72. PMID: 10977869.

Alexander W, Bernstein KE, Catt KJ, de Gasparo M, Dhanachandra Singh K, Eguchi S, Escher E, Goodfriend TL, Horiuchi M, Hunyady L, Husain A, Inagami T, Karnik S, Kemp J, Thomas WG, Timmermans PBMWM, Tirupula K, Unal H, Unger T, Vanderheyden P. Angiotensin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4).

Recently viewed